Organogenesis Holdings Inc.
جودة البيانات: 100%
ORGO
NASDAQ
Manufacturing
Chemicals
KWD 2.34
▼
KWD 0.05
(-1.89%)
القيمة السوقية: 295.23 M
السعر
KWD 2.30
القيمة السوقية
295.23 M
نطاق اليوم
—
نطاق 52 أسبوعًا
—
حجم التداول
—
فتح —
متوسط 50 يوم / 200 يوم
—
متوسط 50 يوم / 200 يوم
—
Quick Summary
النقاط الرئيسية
Revenue grew 4.78% annually over 5 years — modest growth
Earnings grew 4201.05% over the past year
ROE of 15.17% — decent returns on equity
Negative free cash flow of -24.46 M
P/E of 7.97 — trading at a low valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 12.26%
النمو
Revenue Growth (5Y)
4.78%
أعلى من متوسط القطاع (1.82%)
Revenue (1Y)17.04%
Earnings (1Y)4201.05%
FCF Growth (3Y)N/A
الجودة
Return on Equity
15.17%
أعلى من متوسط القطاع (-54.01%)
ROIC8.65%
Net Margin6.56%
Op. Margin7.92%
الأمان
Debt / Equity
N/A
Current Ratio3.32
Interest Coverage19.59
التقييم
PE (TTM|NTM|2027)
7.97 | 8.21 | 7.93
أعلى من متوسط القطاع (-1.49)
P/B Ratio1.16
EV/EBITDA3.86
Dividend YieldN/A
تاريخ السعر
الاتجاهات المالية
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1385 نظير)
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1385 نظير)| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | 8.0 | -1.5 |
| P/B | 1.2 | 1.6 |
| ROE % | 15.2 | -54.0 |
| Net Margin % | 6.6 | -41.5 |
| Rev Growth 5Y % | 4.8 | 1.8 |
| D/E | — | 0.3 |
السعر المستهدف للمحللين
محلل 1
Buy
الحالي
KWD 2.34
المستهدف
KWD 8.00
KWD 8.00
KWD 8.00
KWD 8.00
التوقعات
مكرر الربحية المستقبلي
8.21
ربحية السهم المستقبلية
KWD 0.29
الإيرادات المقدّرة
506.60 M
تقديرات الأرباح
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| FY2027 |
KWD 0.29
KWD 0.29 – KWD 0.29
|
506.60 M | 1 |
| FY2026 |
-KWD 0.17
-KWD 0.17 – -KWD 0.17
|
401.20 M | 1 |
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| 2026 Q2 |
-KWD 0.09
-KWD 0.09 – -KWD 0.09
|
80.50 M | 1 |
| 2026 Q1 |
-KWD 0.29
-KWD 0.29 – -KWD 0.29
|
43.30 M | 1 |
مفاجآت الأرباح
آخر 4 أرباع
| الربع | EPS المقدر | EPS الفعلي | المفاجأة |
|---|---|---|---|
| Q42025 | KWD 0.21 | KWD 0.40 | +90.5% |
| Q32025 | KWD 0.07 | KWD 0.18 | +153.6% |
| Q22025 | -KWD 0.01 | -KWD 0.06 | -491.0% |
| Q12025 | -KWD 0.03 | -KWD 0.11 | -254.7% |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 17.04% | Revenue Growth (3Y) | 14.13% |
| Earnings Growth (1Y) | 4201.05% | Earnings Growth (3Y) | 173.66% |
| Revenue Growth (5Y) | 4.78% | Earnings Growth (5Y) | -20.96% |
| Profitability | |||
| Revenue (TTM) | 564.17 M | Net Income (TTM) | 37.03 M |
| ROE | 15.17% | ROA | 7.63% |
| Gross Margin | N/A | Operating Margin | 7.92% |
| Net Margin | 6.56% | Free Cash Flow (TTM) | -24.46 M |
| ROIC | 8.65% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 3.32 |
| Interest Coverage | 19.59 | Asset Turnover | 1.16 |
| Working Capital | 209.43 M | Tangible Book Value | 216.41 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | 7.97 | Forward P/E | 8.21 |
| P/B Ratio | 1.16 | P/S Ratio | 0.52 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | 3.86 | Fwd EV/EBITDA | N/A |
| Forward P/S | 0.58 | Fwd Earnings Yield | 12.18% |
| FCF Yield | -8.29% | ||
| Market Cap | 295.23 M | Enterprise Value | 231.49 M |
| Per Share | |||
| EPS (Diluted TTM) | 0.15 | Revenue / Share | 4.39 |
| FCF / Share | -0.19 | OCF / Share | -0.08 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | -32.20% |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 2.51% | FCF Conversion | -66.05% |
| SBC-Adj. FCF | -36.15 M | Growth Momentum | 12.26 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 564.17 M | 482.04 M | 433.14 M | 450.89 M | 468.06 M |
| Net Income | 37.03 M | 861,000.0 | 4.95 M | 15.53 M | 94.90 M |
| EPS (Diluted) | 0.15 | -0.01 | 0.04 | 0.12 | 0.71 |
| Gross Profit | — | 366.30 M | 326.66 M | 345.87 M | 353.86 M |
| Operating Income | 44.69 M | -1.28 M | 12.53 M | 22.30 M | 72.92 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 44.54 M | 50.27 M | 44.38 M | 39.76 M | 30.74 M |
| SG&A Expenses | 326.24 M | 294.51 M | 269.75 M | 283.81 M | 250.20 M |
| D&A | 15.27 M | 13.62 M | — | — | — |
| Interest Expense | -2.28 M | 1.54 M | 2.19 M | 2.01 M | 7.24 M |
| Income Tax | 9.94 M | -3.67 M | 5.45 M | 4.75 M | -31.12 M |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 598.73 M | 497.89 M | 460.03 M | 449.36 M | 443.26 M |
| Total Liabilities | 164.81 M | 112.57 M | 181.36 M | 183.69 M | 201.22 M |
| Shareholders' Equity | 300.13 M | 262.90 M | 278.66 M | 265.67 M | 242.04 M |
| Total Debt | — | — | 66.56 M | 71.25 M | 74.06 M |
| Cash & Equivalents | 93.68 M | 135.57 M | 103.84 M | 102.48 M | 113.93 M |
| Current Assets | 362.19 M | 285.94 M | 225.04 M | 222.61 M | 226.98 M |
| Current Liabilities | 100.12 M | 77.48 M | 80.51 M | 75.02 M | 82.01 M |
درجات الاستراتيجيات
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
#116 of 245
النشاط الأخير
دخل
Price/Sales Ratio Focus (Ken Fisher)
Apr 12, 2026
{"event":"ticker_viewed","properties":{"ticker":"ORGO","listing_kind":"stock","pathname":"/stocks/orgo","exchange":"NASDAQ","country":"US"}}